ubiquitin conjugating enzyme E2 M pseudogene 1Genealiases: []
Q-omics provides the consensus-scored UBE2MP1 profile across patient tissues and cancer cell-line models. UBE2MP1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, UBE2MP1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, UBE2MP1 RNA expression shows 17,042 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, KIRC, and ACC as cancer lineages where UBE2MP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2MP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2MP1 survival associations across molecular data types. UBE2MP1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2MP1 RNA expression–survival associations across cancer types. High UBE2MP1 expression shows unfavorable associations in LUAD, LIHC, KIRP, ACC, MESO and LGG. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for UBE2MP1 RNA expression.
This table summarizes UBE2MP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for UBE2MP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2MP1 shows higher tumor expression in KIRC, HNSC, LIHC, BRCA, COAD and LUAD. The KIRC box plot shows higher UBE2MP1 RNA expression in tumor versus normal tissue (log2 FC = +0.486, t-test p < 0.001).
This table shows molecular features associated with UBE2MP1 in patient tissues and cancer cell lines. In patient samples, UBE2MP1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE2MP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in CNS.
